Hematologic Oncology | Specialty

Dr. Seet on the Need for Long-Term Outcome Data Regarding Treatment Discontinuation in CML

August 28th 2019

Christopher S. Seet, MD, PhD, hematologist and oncologist, UCLA Health, discusses the need for long-term outcome data pertaining to treatment discontinuation in chronic myeloid leukemia (CML).

Dr. Schiller on the Importance of Genomic Testing in AML

August 23rd 2019

Gary J. Schiller, MD, director, Bone Marrow/Stem Cell Transplantation and professor of hematology/oncology, David Geffen School of Medicine, UCLA, underscores the importance of genomic testing in acute myeloid leukemia.

Dr. Rossetti on Risk Stratification in Myeloproliferative Neoplasms

August 20th 2019

James M. Rossetti, DO, hematologist, UPMC Hillman Cancer Center, discusses risk stratification in myeloproliferative neoplasms (MPNs).

Dr. Zain on Investigational Approaches in Peripheral T-Cell Lymphoma

August 16th 2019

Jasmine M. Zain, MD, hematologist/oncologist, associate clinical professor, Hematology and Hematopoietic Cell Transplantation, and director, T cell Lymphoma program, City of Hope, discusses investigational approaches in peripheral T-cell lymphoma.

Dr. Mesa on the FDA Approval of Fedratinib in Myelofibrosis

August 16th 2019

Ruben A. Mesa, MD, director, The Mays Cancer Center, the newly named center of UT Health San Antonio MD Anderson Cancer Center, discusses the FDA approval of fedratinib (Inrebic) in myelofibrosis.

FDA Approves Fedratinib for Myelofibrosis

August 16th 2019

The FDA has approved fedratinib (Inrebic) for the treatment of adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis.

Dr. Pullarkat on Treatment Strategies in Transplant Ineligible ALL

August 15th 2019

Vinod A. Pullarkat, MD, clinical professor of Hematology & Hematopoietic Cell Transplantation, and hematologist/oncologist, City of Hope, discusses treatment strategies in transplant ineligible acute lymphoblastic leukemia (ALL).

AML Findings Suggest a Broader Role for Genomic Testing

August 15th 2019

Genomic profiling provides evidence of measurable residual disease in patients with acute myeloid leukemia and may help guide the choice of a preconditioning regimen in those who are at risk of relapse after undergoing allogeneic hematopoietic cell transplantation.

Dr. Castillo on Emerging Treatment Approaches in Waldenstrom Macroglobulinemia

August 14th 2019

Jorge J. Castillo, MD, clinical director, Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, and associate professor of medicine, Harvard Medical School, highlights ongoing research with emerging treatment approaches in Waldenström macroglobulinemia.

Dr. Snyder on Mainstays of Treatment in Polycythemia Vera

August 14th 2019

David S. Snyder, MD, associate chair and professor, Department of Hematology and Hematopoietic Cell Transplantation, and hematologist/oncologist, City of Hope, discusses mainstays of treatment in polycythemia vera (PV).

Identifying Patients and Treating With CAR T-Cell Therapy

August 13th 2019

Stem Cell Transplantation and Novel Therapy

August 13th 2019

Optimizing Therapy for Patients With Multiple Myeloma

August 13th 2019

Navigating Through Testicular Cancer Treatment

August 13th 2019

CML Paradigm Transforms With New Treatments, Potential for TKI Discontinuation

August 9th 2019

Jorge Cortes, MD, discusses frontline advances, discontinuation, and remaining challenges in the chronic myeloid leukemia paradigm.

Dr. Chao on Minimal Residual Disease in ALL

August 9th 2019

Nelson Jen An Chao, MD, professor of medicine, Donald D. and Elizabeth G. Cooke Cancer Research Professor, chief, Division of Cell Therapy in the Department of Medicine, Duke Cancer Institute, discusses minimal residual disease (MRD) in acute lymphoblastic leukemia (ALL).

Experts Discuss Highly Anticipated Study Results Across Tumor Types

August 5th 2019

OncLive interviewed experts at the State of the Science Summits in July 2019 on highly anticipated clinical trial results across tumor types.

NCCN Guidelines Set New Pace for Pediatric ALL

August 4th 2019

With the recent publication of an inaugural set of guidelines for treatment of pediatric acute lymphoblastic leukemia, the National Comprehensive Cancer Network seeks to introduce standards to a branch of care long dominated by clinical trial protocols.

Dr. Straus on the 3-Year Results of the ECHELON-1 Study in Hodgkin Lymphoma

July 31st 2019

David J. Straus, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the 3-year follow-up results of the ECHELON-1 study, which examines brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma.

Dr. Neelapu on Third-Line CAR T-Cell Therapy in Large B-Cell Lymphoma

July 31st 2019

Sattva Neelapu, MD, discusses the use of CAR T-cell therapy in the third-line setting for patients with large B-cell lymphoma.